B Cell Lymphoma
From the Journals
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL
The combination of venetoclax and ibrutinib outperformed previous reports of either of the two agents alone.
News
FDA approves lenalidomide/rituximab for previously treated FL, MZL
The approval is based on results from the phase 3 AUGMENT trial, which compared the combination treatment with placebo in previously treated...
From the Journals
Genetic analysis identifies prognostic markers in CLL
A single 11q22 deletion, lacking an ATM mutation on the other allele, had the shortest progression-free survival among patients with CLL who were...
From the Journals
CD23 expression linked to improved survival in MCL
Researchers found that mantle cell lymphoma cases that were CD23 positive had a higher frequency of leukemic nonnodal presentation and CD200...
From the Journals
Trial follow-up spotlights survival gains in follicular lymphoma
The 13-year update to the GITMO-IIL trial showed the important role of complete remission in prolonged survival. This is the longest follow-up...
News
FDA approves venetoclax/obinutuzumab combo for CLL
Venetoclax/obinutuzumab was compared with venetoclax/chlorambucil in the CLL14 study and showed superior progression-free survival in previously...
From the Journals
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
From the Journals
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...
Opinion
Lessons from KEYNOTE-158 and the role of R-CHOP
Dr. Alan P. Lyss breaks down the clinical relevance of two recent studies in advanced cervical cancer and diffuse large B-cell lymphoma.
Conference Coverage
High-dose MTX-based chemo is well tolerated in older PCNSL patients
GLASGOW – A retrospective, real-world study suggests that older, fit patients can tolerate an intensive treatment regiment for primary central...
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...